Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens.
Vidal-Crespo A, Matas-Céspedes A, Rodriguez V, Rossi C, Valero JG, Serrat N, Sanjuan-Pla A, Menéndez P, Roué G, López-Guillermo A, Giné E, Campo E, Colomer D, Bezombes C, van Bueren JL, Chiu C, Doshi P, Pérez-Galán P.
Vidal-Crespo A, et al.
Haematologica. 2020 Apr;105(4):1032-1041. doi: 10.3324/haematol.2018.211904. Epub 2019 Jul 11.
Haematologica. 2020.
PMID: 31296574
Free PMC article.